WallStreetZenWallStreetZen

NASDAQ: STRO
Sutro Biopharma Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for STRO

Based on 8 analysts offering 12 month price targets for Sutro Biopharma Inc

Min Forecast
$27.00+28.33%
Avg Forecast
$47.75+126.95%
Max Forecast
$60.00+185.17%

Should I buy or sell STRO stock?

Based on 8 analysts offering ratings for Sutro Biopharma Inc.

Strong Buy
Strong Buy
4 analysts 50%
Buy
4 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although STRO's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates STRO as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -6.47% per year. Learn More

Be the first to know when Wall Street analysts revise their STRO stock forecasts and price targets.

STRO stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-08-13
lockedlocked$00.00+00.00%2026-08-13
lockedlocked$00.00+00.00%2026-06-11
lockedlocked$00.00+00.00%2026-05-28
lockedlocked$00.00+00.00%2026-05-15
HC Wainwright & Co.
Top 5%
96
BuyMaintains$50.00+137.64%2026-05-15
Mizuho
Top 39%
62
BuyInitiates Coverage On$50.00+137.64%2026-04-30
Deutsche Bank
Top 29%
72
Strong BuyMaintains$55.00+161.41%2026-03-25
Wells Fargo
Top 5%
96
Strong BuyUpgrades$27.00+28.33%2026-03-24Find out why

1 of 1

Forecast return on equity

Is STRO forecast to generate an efficient return?

Insufficient data to display

Forecast return on assets

Is STRO forecast to generate an efficient return on assets?

Company
-63.32%
Industry
23.16%
STRO is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

STRO earnings per share forecast

What is STRO's earnings per share in the next 3 years based on estimates from 15 analysts?

Avg 1 year Forecast
-$8.70
Avg 2 year Forecast
-$7.54
Avg 3 year Forecast
-$7.44

STRO revenue forecast

What is STRO's revenue in the next 3 years based on estimates from 14 analysts?

Avg 1 year Forecast
$45.4M-0.56%
Avg 2 year Forecast
$41.1M-10.12%
Avg 3 year Forecast
$28.3M-38.14%
STRO's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

STRO revenue growth forecast

How is STRO forecast to perform vs Biotechnology companies and vs the US market?

Company
-12.98%
Industry
32.4%
Market
13.27%
STRO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
STRO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

STRO vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
STRO$21.04$47.75+126.95%Strong Buy
ABEO$6.09$20.50+236.62%Buy
DMAC$6.52$12.00+84.05%Buy
SABS$3.78$12.29+225.03%Strong Buy
IMRX$5.30$17.33+227.04%Strong Buy
View Top Biotech Stocks

Sutro Biopharma Stock Forecast FAQ

Is Sutro Biopharma Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 8 Wall Street analysts covering (NASDAQ: STRO) stock is to Strong Buy STRO stock.

Out of 8 analysts, 4 (50%) are recommending STRO as a Strong Buy, 4 (50%) are recommending STRO as a Buy, 0 (0%) are recommending STRO as a Hold, 0 (0%) are recommending STRO as a Sell, and 0 (0%) are recommending STRO as a Strong Sell.

If you're new to stock investing, here's how to buy Sutro Biopharma stock.

What is STRO's earnings growth forecast for 2026-2028?

(NASDAQ: STRO) Sutro Biopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.47%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 30.28%.

Sutro Biopharma's earnings in 2026 is -$180,636,000.On average, 15 Wall Street analysts forecast STRO's earnings for 2026 to be -$144,305,931, with the lowest STRO earnings forecast at -$165,420,394, and the highest STRO earnings forecast at -$96,626,774. On average, 15 Wall Street analysts forecast STRO's earnings for 2027 to be -$124,945,756, with the lowest STRO earnings forecast at -$173,057,682, and the highest STRO earnings forecast at -$84,613,716.

In 2028, STRO is forecast to generate -$123,368,887 in earnings, with the lowest earnings forecast at -$167,370,340 and the highest earnings forecast at -$72,948,862.

What is STRO's revenue growth forecast for 2026-2028?

(NASDAQ: STRO) Sutro Biopharma's forecast annual revenue growth rate of -12.98% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.4%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.27%.

Sutro Biopharma's revenue in 2026 is $45,702,000.On average, 14 Wall Street analysts forecast STRO's revenue for 2026 to be $753,531,316, with the lowest STRO revenue forecast at $235,618,440, and the highest STRO revenue forecast at $1,204,787,885. On average, 14 Wall Street analysts forecast STRO's revenue for 2027 to be $681,071,599, with the lowest STRO revenue forecast at $0, and the highest STRO revenue forecast at $1,240,835,351.

In 2028, STRO is forecast to generate $468,733,123 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $1,201,305,839.

What is STRO's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: STRO) forecast ROA is -63.32%, which is lower than the forecast US Biotechnology industry average of 23.16%.

What is STRO's Price Target?

According to 8 Wall Street analysts that have issued a 1 year STRO price target, the average STRO price target is $47.75, with the highest STRO stock price forecast at $60.00 and the lowest STRO stock price forecast at $27.00.

On average, Wall Street analysts predict that Sutro Biopharma's share price could reach $47.75 by Aug 13, 2027. The average Sutro Biopharma stock price prediction forecasts a potential upside of 126.95% from the current STRO share price of $21.04.

What is STRO's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: STRO) Sutro Biopharma's current Earnings Per Share (EPS) is -$17.36. On average, analysts forecast that STRO's EPS will be -$8.70 for 2026, with the lowest EPS forecast at -$9.98, and the highest EPS forecast at -$5.83. On average, analysts forecast that STRO's EPS will be -$7.54 for 2027, with the lowest EPS forecast at -$10.44, and the highest EPS forecast at -$5.10. In 2028, STRO's EPS is forecast to hit -$7.44 (min: -$10.09, max: -$4.40).

What is STRO's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: STRO) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.